Navigation Links
Nektar's Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
Date:11/14/2007

Nektar Highlights Innovative New Product Development in the Areas of

Oncology, Anti-Infectives, CNS and Pain Therapies

NEW YORK, Nov. 14 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) showcased its two industry-leading Pulmonary and PEGylation technology platforms and the company's innovative proprietary product pipeline at its R&D Day held today at The Palace Hotel in New York.

"Nektar's R&D Day presentation emphasizes our world-class talent and innovative work in the development of breakthrough biopharmaceuticals that leverage our two technology platforms," said Howard W. Robin, President and Chief Executive Officer of Nektar. "Our ground-breaking work in small molecule PEGylation represent significant value for Nektar and promises to result in great improvements to many drugs."

During the event, Nektar scientists and drug development experts highlighted Nektar's pioneering research in the area of small molecule PEGylation and the company's initial market applications of this innovative technology platform in oncology and central nervous system (CNS) therapeutics.

Company Previews NKTR-102 and NKTR-118 Phase 2 Trial Designs

Nektar also previewed its proprietary product clinical development programs, including the Phase 2 clinical trial designs for NKTR-102 (PEG- irinotecan), the company's lead oncolytic candidate under development for the treatment of solid tumors, and NKTR-118 (oral PEG naloxol) for opioid bowel dysfunction.

Nektar Chief Operating Officer and Head of the PEGylation Business Unit, Hoyoung Huh, M.D., Ph.D. said, "Based on positive Phase 1 results with our two lead PEG products that leverage our important research in small molecule PEGy
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
2. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
3. Leading Child Abuse Center Releases Back to School Tips to Protect Children From Internet Predators
4. Leading-edge body sensor could help produce sporting champions
5. Hospital Quality Info on Web Can Be Misleading
6. AT&T Establishes New Network Services for Leading Medical Liability Insurer
7. Video and Photo: Leading CEOs Launch Alliance With American Red Cross to Strengthen Nations Preparedness for Disasters
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. Sentillion Positioned in Visionaries Quadrant in Leading Industry Analyst Firms User Provisioning Magic Quadrant
10. Leading Asthma and Allergy Author and Counselor Joins The HealthCentral Network As Expert
11. Long Term Care Insurance Gains Momentum Thanks to State Promotions, a Leading Brokerage Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2008)...stained Energy Enhancing Supplement, BOCA RATON, ...sed,nutritional supplement manufacturer, introduce...., Glyc,n Go, is the first and only chewable form...t, and the effects that it has on the,energy syste...trainers,around the globe., In clinical trials, t...
(Date:10/13/2008)...wswire/ -- NeoVista, Inc., presented,yesterday the...l,brachytherapy device on choroidal neovascular le...tina Specialist,s (ASRS) 26th Annual Meeting. The,...S., of The Methodist,Hospital, Houston, Texas, dem...y and ocular coherence tomography (OCT) in many pa...
(Date:10/13/2008)...taJobs.com and numerous newspaper affiliates have ...com . AtlantaJobs.com is the newest online job bo...bseekers in the metro Atlanta area. , ...-- AtlantaJobs.com and numerous newspaper affili...aJobs.com is the newest online job board dedicate...
(Date:10/12/2008)... Five neonatology fellows have been awarded grants...e area of follow-up care of the premature infant a...ts, which underscore MedImmune,s commitment to exp...ovide each recipient,s institution a $35,000 grant...recipients were acknowledged on Sunday, October 12...
Breaking Medicine News(10 mins):Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 2Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 3Health News:Atlanta Area Job Board Launches New Local Job Board to Connect Local Employers and Jobseekers 2Health News:MedImmune grants 5 new fellowships to help expand premature infant follow-up care research 2
...ts. Now, BT Offices and Vans will sport an anti-sm...ng is banned in the BT premises as well as in the ...tantly, this move might encourage “anti-smoking” i...n. The anti-smoking activists have seconded this ...
... improvement with Viagra could now benefit from st...ighlight the use of statins for management of endo...m erectile dysfunction. The result of this small, ...ennsylvania researchers is published in the Journa...
... Railways to take off chicken and egg related dish...n issued to all the Zonal Railways and other railw...fficial quoted that such a decision was taken upon...rest. As the disease itself is highly contagious,...
...construct a world-class cancer hospital and resear...come up at Rajarhat,// at the cost of Rs. 1.2 bill... Centre (TMC) would come up on a 10-acre plot, Wes...tacharjee and Tata Group chairman Ratan Tata said,...
Other Medicine News:Health News:Statins For Erectile Dysfunction- An Alternative To Viagra? 2
(Date:10/12/2008)...and WASHINGTON, Oct. 12 /- ...announced results from an analysis,of nearly 7,500..., which,are designed to confirm the performance of...nary Stent System in real-world practice. The,two-...t reduced clinical,restenosis in patients with dia...
(Date:10/10/2008)...Mich., Oct. 10 /- Diplomat Specialty,...s selected Diplomat,Specialty Pharmacy to be one o..., national Therapy Optimization Study for Multiple...OP MS study, is to examine the benefits of a,speci...ance, adherence and,patient outcomes. Targeted pat...
(Date:10/10/2008)..., Oct. 10 /- Inverness Medi...vider of near-patient,diagnostics, monitoring and ...n Ki-moon, the Secretary-General of the United Nat...eventeen of the world,s leading,research-based and...Inverness, together with senior officials from the...
(Date:10/10/2008)...lif., Oct. 10 /- TriReme Medical Inc.... to affix the CE (Conformite,Europeenne) marking a...y,Stent System, a unique main vessel stent system ...urcations., Representing the next generation in b...tential use in a quarter of the 2.2 million,angiop...
Breaking Medicine Technology:TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5Diplomat Specialty Pharmacy Tapped by Teva Neuroscience for Therapy Optimization Study for Multiple Sclerosis (TOP MS) 2Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 2Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 3TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2Leading Childrens Hospital Utilizes MEDais Solutions to Deliver Outstanding Care 4025 1Leading Childrens Hospital Utilizes MEDais Solutions to Deliver Outstanding Care 4025 2Nventa updates progress of cervical dysplasia trial with new HspE7 1339 1Nventa updates progress of cervical dysplasia trial with new HspE7 1339 2Nventa updates progress of cervical dysplasia trial with new HspE7 1339 3Nventa updates progress of cervical dysplasia trial with new HspE7 1339 4Nventa updates progress of cervical dysplasia trial with new HspE7 1339 5Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 1Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 2Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 3FDA Panel Mulls Ban on Kids Cold Medicines 4019 1FDA Panel Mulls Ban on Kids Cold Medicines 4019 2FDA Panel Mulls Ban on Kids Cold Medicines 4019 3FDA Panel Mulls Ban on Kids Cold Medicines 4019 4
... Data presented at the 11th International Myeloma ... activity of perifosine in,combination with bortez...asone, in patients with relapsed/refractory multip... relapsed/refractory,Waldenstrom,s macroglobulinem... -- Keryx,Biopharmaceuticals, Inc. today announced...
... IRVING, Texas--(BUSINESS WIRE)--Jun 29, 2007 - Re...entation of new,preclinical data showing their lea...A 402, is effective at protecting against,common t... This,data was presented at the annual meeting of ...n Cancer (MASSC) in St Gallen,Switzerland., Reata...
Other Medicine Technology:Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 3Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 4Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 6Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 7RTA 402 Shown to Protect Animals Against Toxicities of Standard,Cancer Treatments 2RTA 402 Shown to Protect Animals Against Toxicities of Standard,Cancer Treatments 3
...ce by physicians in office based electrosurgery fo...e power settings, maintain the sterile field and d... to control the function and output of the Hyfreca...d or safety issue is detected. Cost effective alte...
...ost powerful isolated ESU on the market with 10,00...ows the surgeon to adjust power settings from the ...r Plus PC Patented Controlled Output Voltage in CU...utting through various impedance tissues with mini...
Microprocessor-based isolated electrosurgical generator, designed for all general surgical procedures. Unit includes the Valleylab adaptive REM system and Instant Response technology.
Black multi-pinhole occluder
Medicine Products: